Financial Ratios

KREBS BIOCHEMICALS & INDUSTRIES LTD.

NSE : KREBSBIOBSE : 524518ISIN CODE : INE268B01013Industry : Pharmaceuticals & DrugsHouse : Private
BSE71.76-0.84 (-1.16 %)
PREV CLOSE ( ) 72.60
OPEN PRICE ( ) 72.61
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1637
TODAY'S LOW / HIGH ( )68.40 74.50
52 WK LOW / HIGH ( )59.3 93.2
NSE72.20-0.2 (-0.28 %)
PREV CLOSE( ) 72.40
OPEN PRICE ( ) 74.70
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 3049
TODAY'S LOW / HIGH( ) 71.55 74.70
52 WK LOW / HIGH ( )59.2 93.95
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)-11.45-20.65-14.45-16.04-12.03
   CEPS(Rs)-8.41-17.73-11.84-13.44-9.39
   DPS(Rs)0.000.000.000.000.00
   Book NAV/Share(Rs)-46.13-34.83-23.91-18.14-8.59
   Tax Rate(%)0.000.000.000.000.00
Margin Ratios
   Core EBITDA Margin(%)-30.27-56.94-32.73-55.53-20.44
   EBIT Margin(%)-41.66-65.55-41.12-68.45-28.74
   Pre Tax Margin(%)-47.36-74.58-52.81-86.41-41.90
   PAT Margin (%)-47.36-74.58-52.81-86.41-41.90
   Cash Profit Margin (%)-34.78-64.03-43.27-72.41-32.68
Performance Ratios
   ROA(%)-13.54-25.51-19.36-20.91-14.92
   ROE(%)0.000.000.000.000.00
   ROCE(%)-28.59-57.38-40.28-56.96-35.41
   Asset Turnover(x)0.290.340.370.240.36
   Sales/Fixed Asset(x)0.180.220.210.140.21
   Working Capital/Sales(x)-1.58-1.40-2.01-1.38-2.00
Efficiency Ratios
   Fixed Capital/Sales(x)5.674.604.697.154.86
   Receivable days4.913.601.7117.0012.36
   Inventory Days131.30128.88107.38130.8779.07
   Payable days378.02263.51305.42507.31309.62
Valuation Parameters
   PER(x)0.000.000.000.000.00
   PCE(x)-6.71-8.09-7.50-6.09-12.36
   Price/Book(x)-1.22-4.12-3.72-4.52-13.50
   Yield(%)0.000.000.000.000.00
   EV/Net Sales(x)5.857.575.306.394.79
   EV/Core EBITDA(x)-20.11-13.77-16.79-11.74-24.27
   EV/EBIT(x)-14.04-11.55-12.90-9.33-16.68
   EV/CE(x)1.742.381.791.601.61
   M Cap / Sales2.335.183.254.414.04
Growth Ratio
   Net Sales Growth(%)-12.6811.1860.72-30.0441.38
   Core EBITDA Growth(%)53.83-93.686.79-92.84-29.29
   EBIT Growth(%)44.50-77.253.45-66.64-8.41
   PAT Growth(%)44.55-57.011.78-44.28-12.27
   EPS Growth(%)44.55-42.899.89-33.307.22
Financial Stability Ratios
   Total Debt/Equity(x)-1.84-1.91-2.37-2.03-3.74
   Current Ratio(x)0.330.450.440.440.56
   Quick Ratio(x)0.080.130.100.090.40
   Interest Cover(x)-7.30-7.26-3.52-3.81-2.18
   Total Debt/Mcap(x)1.510.460.640.450.28

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.